The rapid digitization of biological data has transformed the landscape of global research, creating a paradigm shift in how scientists across the globe interact with the natural world. As the international community prepares for the 17th Conference of the Parties (COP17) to the Convention on Biological Diversity (CBD), the debate over Digital Sequence Information (DSI) has moved to the forefront of the diplomatic and economic agenda. Genetic sequences and information derived from plants, animals, microorganisms, and other biological resources are no longer just physical assets stored in botanical gardens or seed banks; they are digital assets stored in massive, open-access databases. These digital blueprints are increasingly used in bio-based research and innovation across a multitude of sectors, including pharmaceuticals, agriculture, cosmetics, and environmental management.
The International Chamber of Commerce (ICC) has issued a call to action, urging governments to ensure that the emerging global system for sharing benefits from DSI is practical, predictable, and proportional. While the public and private sectors both rely heavily on these digital resources to complement research involving physical samples, the transition from physical to digital has created a legal gray area. The Convention on Biological Diversity originally established frameworks to ensure that the benefits of using physical genetic resources were shared fairly with the countries of origin—a concept formalized in the Nagoya Protocol. However, as technology has advanced, these existing national regulations have proven difficult to apply to digital data, which can be shared across borders at the click of a button.
The Digital Transformation of Biological Research
To understand the urgency of the ICC’s position, one must consider the practical application of DSI in modern science. When a researcher sequences the genome of a drought-resistant plant in the Amazon, a pathogenic virus in a dense urban center, or a unique microorganism found in deep-sea hydrothermal vents, that data is typically uploaded to a public database. Once online, this information allows researchers globally to access the data digitally without ever needing to touch a physical specimen. This open-access model has been credited with accelerating the development of life-saving vaccines, climate-resilient crops, and sustainable biofuels.
However, the ease of access has led to concerns among biodiversity-rich nations, primarily in the Global South. These nations argue that if a commercial product is developed using the genetic sequence of a species native to their land, they should receive a portion of the profits to fund conservation efforts. This is the "benefit-sharing" mandate that the CBD is currently attempting to codify into a new global mechanism. The challenge lies in creating a system that rewards the custodians of biodiversity without stifling the very innovation that makes those resources valuable.
The ICC Position: Seeking Legal Certainty and Proportionality
As governments move toward the operationalization of this new mechanism at COP17, the ICC is emphasizing the need for a framework that provides legal certainty. For the business community, the primary risk is a fragmented regulatory landscape where different countries impose conflicting requirements on the use of digital data. Such a scenario could lead to "patent thickets" or legal disputes that discourage investment in bio-based research.
The ICC is calling for a mechanism that prioritizes three core pillars: legal certainty, clarity, and proportionality. Business leaders argue that the mechanism must be simple enough for small and medium-sized enterprises (SMEs) to navigate while being robust enough to handle the complexities of multinational research and development. Furthermore, the ICC is urging COP17 negotiators to avoid "duplicate obligations," where a company might be forced to pay benefit-sharing fees multiple times for the same resource under different national and international laws.
Chronology of the DSI Debate: From Rio to Cali and Beyond
The journey toward a global DSI mechanism has been decades in the making, reflecting the evolution of biotechnology itself.
- 1992: The Rio Earth Summit. The Convention on Biological Diversity (CBD) is adopted, establishing the principle that states have sovereign rights over their biological resources and that benefits from their use should be shared.
- 2010: The Nagoya Protocol. This supplementary agreement to the CBD was adopted to provide a legal framework for "Access and Benefit-Sharing" (ABS). However, its focus remained largely on physical samples.
- 2016-2018: The Emergence of DSI. During COP13 and COP14, parties began to officially recognize that the use of digital sequence information was a critical issue that the Nagoya Protocol did not fully address.
- 2022: The Kunming-Montreal Global Biodiversity Framework (GBF). At COP15, a historic agreement was reached to protect 30% of the planet’s land and oceans by 2030. Crucially, parties agreed to establish a multilateral mechanism for benefit-sharing from the use of DSI.
- 2024: COP16 in Cali, Colombia. Negotiators worked to define the "Cali Fund," a global fund into which users of DSI would contribute. While progress was made on the fund’s structure, many technical details regarding the "trigger" for payments and the percentage of revenue remained unresolved.
- Upcoming: COP17. This summit is expected to be the milestone where the mechanism becomes fully operational, moving from theoretical framework to active global policy.
Supporting Data: The Economic Stakes of the Bio-Economy
The importance of DSI to the global economy cannot be overstated. According to various economic analyses, the "bio-economy"—sectors that rely on biological resources—contributes trillions of dollars to global GDP.
- Database Growth: The International Nucleotide Sequence Database Collaboration (INSDC), which includes GenBank, the European Nucleotide Archive, and the DNA Data Bank of Japan, currently hosts over 200 million sequences. The volume of data is estimated to double every 18 months.
- Pharmaceutical Impact: It is estimated that approximately 25% to 50% of all pharmaceutical drugs are derived from natural products or their derivatives. The ability to screen these compounds digitally saves years of lab work and billions in R&D costs.
- Agricultural Innovation: With the global population expected to reach 9.7 billion by 2050, DSI is critical for developing crops that can survive extreme weather. The global seeds market, heavily reliant on genetic data, is valued at over $60 billion annually.
- Conservation Funding Gap: The United Nations estimates a $700 billion annual funding gap for biodiversity conservation. A successful DSI mechanism could potentially funnel billions of dollars from the private sector into the Global South to protect the ecosystems that provide these genetic sequences.
Official Responses and Stakeholder Perspectives
The debate over DSI has created a complex web of alliances and tensions. While the ICC represents the interests of the private sector, other groups have voiced distinct concerns.
The Scientific Community, represented by organizations like the DSI Scientific Network, has expressed fear that any mechanism that restricts access to databases could hinder public health research. They argue that "open access" is a fundamental principle of science and that any benefit-sharing should be decoupled from the act of accessing the data itself.
Developing Nations (The Group of 77 and China) have maintained that benefit-sharing is a matter of equity. They point out that for decades, companies in the Global North have utilized genetic information from the Global South to create profitable products without providing adequate compensation to the nations that preserved that biodiversity.
Environmental NGOs have generally supported a mandatory contribution system. Groups like the World Wildlife Fund (WWF) argue that the private sector must pay its "fair share" for the "ecosystem services" provided by nature, noting that without financial incentives for conservation, the biological resources that businesses depend on will eventually disappear.
Broader Impact and the Path to COP17
The outcome of the COP17 negotiations will have far-reaching implications for the future of innovation. If the resulting mechanism is too burdensome, it could lead to "de-sequencing," where companies move away from biological research in favor of synthetic or chemical alternatives to avoid legal headaches. This would not only hurt the bio-economy but also reduce the funds available for conservation.
Conversely, a successful mechanism could create a virtuous cycle. By providing a clear, streamlined process for benefit-sharing, the global community can encourage more businesses to participate in bio-based innovation. The ICC’s call for expanding the mechanism to cover more countries and a broader range of data reflects a desire for a "level playing field." If the mechanism is truly global, it minimizes the risk of companies "jurisdiction shopping" for countries with the laxest regulations.
The ICC has emphasized that for business participation to be "attractive," the system must avoid duplicate obligations. In the current landscape, a company might face one set of rules under the CBD, another under the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework, and yet another under the upcoming "Pandemic Treaty." Harmonizing these various international agreements is a priority for industry leaders who seek a single, predictable window for compliance.
As the world edges closer to COP17, the pressure is on negotiators to deliver a framework that satisfies the dual demands of social equity and economic efficiency. The "Cali Fund" and the broader DSI mechanism represent a bold experiment in global governance—an attempt to place a value on the information that encodes life itself. For the International Chamber of Commerce and the thousands of businesses it represents, the goal remains clear: a system that ensures the benefits of nature are shared, while the engine of human innovation continues to turn.
About the Author
